Profile data is unavailable for this security.
About the company
Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.
- Revenue in HKD (TTM)2.57bn
- Net income in HKD429.31m
- Incorporated1998
- Employees2.51k
- LocationJoinn Laboratories China Co LtdA5 Rongjing East StreetEconomic-Technological Development AreaBEIJING 100176ChinaCHN
- Phone+86 1 067869582
- Fax+86 1 067869966
- Websitehttps://www.joinnlabs.com/
More ▼
Holder | Shares | % Held |
---|---|---|
APG Asset Management NVas of 31 Aug 2022 | 5.86m | 4.92% |
Brown Brothers Harriman & Co. (Investment Management)as of 05 Mar 2024 | 5.73m | 4.82% |
UBS Asset Management (Hong Kong) Ltd.as of 19 Mar 2024 | 5.45m | 4.58% |
UBS SDIC Fund Management Co., Ltd.as of 30 Jun 2023 | 4.08m | 3.43% |
FIL Investment Management (Singapore) Ltd.as of 06 Mar 2024 | 3.67m | 3.08% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 3.66m | 3.08% |
FIL Investment Management (Hong Kong) Ltd.as of 06 Mar 2024 | 3.36m | 2.82% |
abrdn Investment Management Ltd.as of 15 Mar 2024 | 3.31m | 2.78% |
Abrdn Asia Ltd.as of 15 Mar 2024 | 1.78m | 1.49% |
BlackRock Advisors (UK) Ltd.as of 24 Apr 2023 | 1.51m | 1.27% |
More ▼
Data from 30 Jun 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.